Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 1

Status

Recruiting 3Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 7Observational 1

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 2

Conditions

Breast Neoplasms 36Triple Negative Breast Neoplasms 32Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 10Urinary Bladder Neoplasms 9Neoplasm Metastasis 7Lung Neoplasms 5Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Glioblastoma 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Uterine Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × sacituzumab govitecan × Clear all
NCT04617522 2026-06-02

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Gilead Sciences

Phase 1 Recruiting
30 enrolled

Neoplasm Metastasis, Liver Failure

NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05143229 2026-05-01

ASSET

University of Kansas Medical Center

Phase 1 Active not recruiting
18 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03964727 2026-04-28

TROPiCS-03

Gilead Sciences

Phase 2 Active not recruiting
227 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT07163481 2025-09-16

SoGreat

Hunan Cancer Hospital

Phase 1 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07151586 2025-09-03

ALTER

UNICANCER

Phase 2 Not yet recruiting
260 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

UNICANCER

Phase 3 Recruiting
96 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡